|
|||||
|
|
Recommendations for the treatment of established fungal infections |
|
| Authors: | K. A. Thursky E. G. Playford J. F. Seymour T. C. Sorrell D. H. Ellis S. D. Guy N. Gilroy J. Chu D. R. Shaw |
| Affiliation: | Department of Infectious Diseases, Peter MacCallum Cancer Centre and St Vincent's Hospital, Melbourne, VIC;; Clinical Research Fellow, Centre for Clinical Research Excellence, Victorian Infectious Diseases Service, Melbourne, VIC.; Infection Management Services, Princess Alexandra Hospital, Brisbane, QLD.; Chair, Haematology Clinical Service, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, VIC.; Centre for Infectious Diseases and Microbiology, University of Sydney, Westmead, NSW; NHMRC Centre of Clinical Research Excellence in Infections and Bioethics in Haematological Malignancies, University of Sydney, Sydney, NSW.; Mycology Unit, Women's and Children's Hospital, North Adelaide, SA.; Pharmacy Department, Royal Adelaide Hospital, Adelaide, SA.; Infectious Diseases and Infection Prevention and Control Units, Royal Adelaide Hospital, Adelaide, SA. |
| Abstract: | Evidence-based guidelines for the treatment of established fungal infections in the adult haematology/oncology setting were developed by a national consensus working group representing clinicians, pharmacists and microbiologists. These updated guidelines replace the previous guidelines published in the Internal Medicine Journal by Slavin et al. in 2004. The guidelines are pathogen-specific and cover the treatment of the most common fungal infections including candidiasis, aspergillosis, cryptococcosis, zygomycosis, fusariosis, scedosporiosis, and dermatophytosis. Recommendations are provided for management of refractory disease or salvage therapies, and special sites of infections such as the cerebral nervous system and the eye. Because of the widespread use newer broad-spectrum triazoles in prophylaxis and empiric therapy, these guidelines should be implemented in concert with the updated prophylaxis and empiric therapy guidelines published by this group. |
| Keywords: | Antifungal therapy invasive mould infections candidiasis aspergillosis consensus guidelines |